Lupin launches Darunavir tablets in US

Global pharma major Lupin Limited announced the launch of Darunavir Tablets, 600 mg and 800 mg, to market a generic equivalent of Prezista Tablets of Janssen Products, LP. 

Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had estimated annual sales of USD 308 million in the U.S. (IQVIA MAT March 2023), the company said in the filing.

Reacting to this news, shares of Lupin were up 2% to hit a 52-week high of Rs 830.3 in Monday's trade.

Meanwhile, the pharma company reported a consolidated net profit of Rs 246.7 crore in Q4FY23. However, the pharma player witnessed strong growth in EBITDA at Rs 615 crore, up by a whopping 117.8% YoY. Its revenue from operations stood at Rs 4,330.30 crore in Q4FY23, rising by 12% from Rs 3,864.50 crore in the same quarter a year ago.

Source: Media reports